XPO1 and acute myeloid leukemia: Further studies are needed to clarify whether the anti-AML effect of selinexor/Exportin 1 inhibition is seen, especially for certain subsets of patients (e.g., elderly patients), and thus whether this strategy should be avoided or employed with reduced dosage in these patients.